MINNEAPOLIS, April 08, 2016 -- On March 3, 2016, Vascular Solutions, Inc., (Nasdaq:VASC) initiated a nationwide recall of Guardian II hemostasis valves used in catheterization procedures. Specific lots of the products have been recalled because they pose an increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death. This recall only affects the Guardian II hemostasis valves and does not include the Guardian II NC hemostasis valves. No injuries have been reported in association with this issue to date.
Healthcare facilities that have the affected Guardian II hemostasis valves should remove the products from their inventory and return them to Vascular Solutions.
The recalled products were manufactured from March 2015 to February 2016 and distributed from April 2015 to February 2016.
The recalled products are specific lots of Model Numbers 8210 and 8211. A listing of the recalled lots is available from Vascular Solutions and has been provided to each facility that purchased the affected products. A total of 26,550 devices have been manufactured, with 5,283 distributed in the United States. The condition that led to the recall may affect approximately 2.4% of recalled devices.
Vascular Solutions Inc. voluntarily initiated the recall on March 3, 2016 through an Urgent Medical Device Recall notification distributed to purchasers of the affected products. The notification identified the specific lots subject to the recall and included instructions on how to return the affected products.
The U.S. Food and Drug Administration (FDA) classified this as a Class I recall. FDA defines Class I recalls as “a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.”
Consumers with questions may contact the company by phone at 1-888-240-6001 Monday through Friday, between the hours of 8:00 a.m. and 5:00 p.m. Central Time or by email at [email protected]. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program:
- Online at http://www.fda.gov/medwatch/report.htm
(form available to fax (1-800-FDA-0178) or mail), or - Call FDA 1-800-FDA-1088 to request a reporting form
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of more than 90 products and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
For further information, connect to www.vasc.com.
Contact: Phil Nalbone VP of Corporate Development Vascular Solutions, Inc. (763) 656-4371


Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million
Want to cut your energy bills? Here’s how five experts are doing it
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
How Technology Is Reshaping Modern Business: From Operations to Customer Experience
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 



